Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409, a Brain-Selective NLRP3 Inhibitor, and Provides Update on BT-267, its LRRK2 Program
Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurodegenerative diseases, today announced the initiation of a first-in-human (FIH) clinical study of BT-409, the company’s novel, brain-selective NOD-, LRR-, and pryin domain-containing protein 3 (NLRP3) inflammasome inhibitor. The company also provided an update on the continued clinical advancement of BT-267, its highly […]